Our Focus
We strategically target key signaling hubs common to multiple tumor types, with a primary focus on the focal adhesion kinase (FAK) and integrin pathways. These pathways are pivotal for tumor cell survival and represent a major cause of treatment resistance across diverse therapeutic approaches. In tandem, we disrupt the tumor-protective microenvironment by selectively targeting cancer-associated fibroblasts (CAFs).
FAK: Key Survival Signaling Hub of Tumor Cell
Cancer is characterized by its exceptional ability to survive through adaptive mechanisms. Focal Adhesion Kinase (FAK), a non-receptor tyrosine kinase, plays a key role in creating a survival advantage for cancer cells. FAK is highly expressed in both tumor cells and cancer-associated fibroblasts (CAFs), and is frequently upregulated or activated by various therapies, including chemotherapy, targeted agents, and radiation. Research indicates that inhibiting the FAK signaling pathway not only synergizes with multiple treatment modalities but also helps overcome emerging resistance to both chemotherapy and targeted therapy.
Targeting Key Signaling Hub of Tumor Defense
Cancer is characterized by its exceptional ability to survive through adaptive mechanisms. Focal Adhesion Kinase (FAK), a non-receptor tyrosine kinase, plays a key role in creating a survival advantage for cancer cells. FAK is highly expressed in both tumor cells and cancer-associated fibroblasts (CAFs), and is frequently upregulated or activated by various therapies, including chemotherapy, targeted agents, and radiation. Research indicates that inhibiting the FAK signaling pathway not only synergizes with multiple treatment modalities but also helps overcome emerging resistance to both chemotherapy and targeted therapy.
Novel Therapeutics Developing Against Key Components of in Tumor Cell Defense
Tumor cell defense consists multiple components, and this can be simplified as three key components, as sensor located in cell membrane, transducer, located in cytoplasm and able to translocate into the center of cells, nucleus, and cells is able to mount a wide array of defense at transcriptional level. Along with tumor cell densive pathway, InxMed is developing drugs targeting at cell membrane, cyctosol and nucleus to maximize its intrinsic synergy. Vertical combinations for broad synergy with ifebemtinib will be a clear differentiation.
Our Publications
Baoyuan Zhang, Zhixiang Zhang, Jiaming Gao, Shiqiang Lu, Ran Pang, Dongfang Li, Xun Huang, Natasha Qin, Leo Liu, Zaiqi Wang 1. iScience, Volume 0, Issue 0, 111536
Gao J, Cheng J, Xie W, Zhang P, Liu X, Wang Z, Zhang B. Expert Opin Investig Drugs. 2024 Jun;33(6):639-651.
Zhang B, Li N, Gao J, Zhao Y, Jiang J, Xie S, Zhang C, Zhang Q, Liu L, Wang Z, Ji D, Wu L, Ren R. J Exp Clin Cancer Res. 2024 Feb 19;43(1):51.
Tan X, Kong D, Tao Z, Cheng F, Zhang B, Wang Z, Mei Q, Chen C, Wu K. Biomark Res. 2024 Jan 25;12(1):13
Gao J, Yao Y, Liu C, Xie X, Li D, Liu P, Wang Z, Zhang B, Ren R. Int J Biol Sci. 2023 May 15;19(9):2711-2724.
Lingying Wu, Jing Wang, Li Wang, Weiguo Lu, Ke Wang, An Lin, Ning Li, Li Li, Ning Su, Shuang Xie, Jun Jiang. ASCO Annual Meeting - April 8-13, 2022
Wu Y, Li N, Ye C, Jiang X, Luo H, Zhang B, Zhang Y, Zhang Q. Discov Oncol. 2021 Nov 22;12(1):52.
Osipov A, Blair AB, Liberto J, Wang J, Li K, Herbst B, Xu Y, Li S, Niu N, Rashid R, Ding D, Liu Y, Wang Z, Wolfgang CL, Burkhart RA, Laheru D, Zheng L. Cancer Biol Med. 2021 Feb 15;18(1):206-214.
Zhang B, Zhang Y, Zhang J, Liu P, Jiao B, Wang Z, Ren R. Adv Sci (Weinh). 2021 Aug;8(16):e2100250.
QUICK LINKS
CONTACT US
Tel: +86 25-58251030
Email: office@inxmed.com
Office address: 73 Tanmi Road Block D-2, 3rd Floor Jiangbei New District, Nanjing
MESSAGE